Eagle Ford Oil & Gas Corporation Signs a $60 Million Debt Facility With Meridian SEZC

OTCBB: ECCE Website: http://www.ssenergyllc.com/
Eagle Ford Oil & Gas Corporation Signs a $60 Million Debt Facility With Meridian SEZC Eagle Ford Oil & Gas Corp. (OTCMarkets:ECCE), a growing independent oil and gas exploration and production company is pleased to announce that Meridian SEZC("Meridian") and ECCE have entered into a definitive agreement through which Meridian will provide up to $60 million of debt with a first draw down scheduled to be $25 million for the purpose of the acquisition and further development of two producing properties located in Madison County and Hardin County, Texas. This securitized commercial debt will be repayable on a straight line basis over 5 years. The arrangement does not require ECCE to issue any new equity. The deal is subject to further due diligence and final documentation and is expected to be completed shortly. Management Comments Mr. Paul Williams, CEO of Eagle Ford Oil and Gas said, "This represents a very significant step forward for the Company and will provide the funds needed for the acquisition and further development of these two producing properties. With this acquisition it immediately adds a much needed revenue stream that will enhance shareholder value." About Meridian SEZC Meridian SEZC is a privately owned finance company located in the Cayman Islands that focuses on resource based, commodity and derivative investments. About Eagle Ford Oil & Gas Corporation Eagle Ford Oil & Gas Corp. engages in exploration and development of oil and gas production properties. The Company specializes in acquiring, exploring and developing oil and gas producing assets in the Gulf Coast region of Texas and Louisiana. Eagle Ford Oil & Gas has a team comprised of senior professionals with distinguished records of achievement and success in the targeted focus area. Forward-Looking Statements Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of ECCE officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future ECCE actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and ECCE has no specific intention to update these statements. CONTACT: Investor Contact: Paul Williams 281-383-9648 About Us Eagle Ford Oil & Gas, out of metropolitan Houston, Texas specializes in acquiring, exploring/analyzing and developing producing oil and gas properties in the Gulf Coast region, specifically in Texas/Louisiana Gulf region. Eagle Ford Oil & Gas was established as an oil and gas developer/operator with a team comprised of senior, experienced professionals with distinguished records of achievement and success, and more specifically in the targeted Texas/Louisiana Gulf region as well as experience on a worldwide basis. The management team, technical team, independent consultants and advisory board members, all have extensive educational backgrounds and degrees, plus comprehensive expertise in domestic and international projects, for Exxon, Atlantic Richfield, Anadarko, Unocal, Marathon, EnCana, Vaquero Oil & Gas, Emory International and so forth. The team members have completed highly successful oil & gas plays. Also, the team members each have an extensive lineage in oil & gas being raised with the business. Mission Statement & Vision Eagle Ford Oil & Gas's mission is to continue to develop, manage and operate oil & gas properties utilizing key risk metrics and detailed geological analysis--not common for smaller businesses--providing investors with a substantive return relative to their invested capital. Eagle Ford Oil & Gas offers an efficient method of development based upon the regional expertise and knowledge of its team. Our vision is to continue to be an important part of the energy production market providing energy while also providing its investor base with returns greater than the relative market. Competitive Advantage Our competitive advantages lie within the following: the experience and expertise of the management team and advisory board, current use of super majors' level geophysics and engineering analysis, the fact that the Company is able to access proven reserves and productive capabilities completely overlooked by the market on a cost-effective basis, the team's ability to add value in its process and finally Eagle Ford's ability to effectively operate at a lower cost. The Company also clearly understands the oil and gas market and knows that in order to be operationally successful there must be systems in place to manage the operations of the projects effectively. The Company's competitive advantages include: it's ability to capture leases at exceptional pricing, its capabilities exceed the market requirements, and it is a strategic platform by which Eagle Ford Oil & Gas has been successful. Company Address:   Eagle Ford Oil & Gas Corp. 2951 Marina Bay Drive Suite 130-369 League City, TX 77573 United States - Map Phone: 281-383-9648 Website: http://www.ssenergyllc.com	Symbol: (OTCBB:ECCE)
Contact James S. Painter III  Emerging Markets Consulting LLC  10724 High Crest Court Howey In The Hills Florida 34737 Office 321-206-6682  Fax 352-429-0691 www.emergingmarketsllc.com  www.themicrocapreport.com Emerging Markets Consulting, LLC ("EMC"), its principals, affiliates, representatives, subcontractors or agents (hereafter referred to as "EMC") prepare and/or assist others in preparing and publishing oral and written information on selected companies (the "Profiled Companies") and/or their securities (the "Securities") in various contexts, including but not limited to corporate and business profiles, summaries, stock alerts, reports, and press releases (hereafter referred to as the "Information") through various methods including but not limited to: (a) facsimile; (b) double opt-in spam compliant emails; (c) mail and courier; and (d) the world wide web, including but not limited to EMC's website at www.emergingmarketsllc.com. Many of the stocks of the Profiled Companies qualify as "penny stocks" under the Securities and Exchange Commission's ("SEC") rules and regulations because, among other things, they have a price of less than $5.00 per share. Penny stocks are subject to important risks that you should be acutely aware of, as detailed in the bullet point presentation below. The Information is disseminated to broker-dealers, members of the general public, readers of our website, and the financial community (collectively the "Recipients") at the direction of the Profiled Companies or third party shareholders of the Profiled Companies and should be used by the Recipients for informational purposes only and even then the Information should only be used as a beginning point for further investigation. This is because EMC: (a) only presents neutral or positive information regarding the Profiled Companies and its business prospects; and (b) does not present the risks or negative aspects associated with the Profiled Company or its securities. Therefore, the Information is in of itself wholly inadequate to formulate any investment decision and we strongly advise against making any investment decisions solely based on the Information. It is imperative that you consult with your professional advisor, including your financial adviser, financial planner or attorney regarding the advisability of investing in any securities, especially with regard to penny stocks. In addition, you should consult with online services that are available free of charge at www.sec.gov, www.pinksheets.com, www.finra.org, Google, or other websites that offer investment guides, valuable information pertaining to penny stocks and penny stock frauds and the risks of investing in penny stocks. Additionally, you should review the quarterly and annual financial and disclosure reports at www.sec.gov, www.otcbb.com and www.pinksheets.com. Statements contained in the Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified by the use of terminology such as "believes", "expects", "may", "will", or "should", or "anticipates". Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Information. The actual results of a Profiled Company's operations, financial condition or other aspects of its business could differ materially from those discussed in the Corporate Information. You should carefully review the bolded disclosure appearing immediately below: EMC always receives compensation from the Profiled Companies or third party shareholders in cash and/or compensation in the Securities in connection with preparation and dissemination of the Information, most frequently in the form of Securities in the name of a Profiled Company. EMC regularly and routinely sells its securities compensation before, during and after its dissemination of the Information regarding the Profiled Companies, most frequently during the dissemination of the Information. You should be acutely aware that EMC repeatedly sells its stock compensation while it is engaged in the dissemination of the Information, as well as before and after such dissemination. Many such securities sales occur during the dissemination of the Information and often occur within minutes, hours or days after EMC first disseminates the Information to the Recipients. EMC's dissemination of the Information has resulted in the past and will in the future result in increases in the Profiled Company's securities trading volume, enabling EMC to sell those Securities at a profit. Additionally, EMC's sale of the Profiled Company's securities concurrently with the dissemination of the Information, including the Profiled Company's profile, may enable EMC to sell at a higher price for such shares, and may result in a diminished value to those buying the Profiled Company's securities.  EMC does not express any opinions, recommendations or viewpoints regarding the Profiled Companies or the Securities, and has not conducted due diligence of any data or information contained in the Information. The Information is based solely upon data and information provided by the Profiled Companies and EMC does not endorse, independently verify, or assert the truthfulness, completeness, accuracy or reliability of the Information. Recipients should not rely on the data or information contained in the Information in making an investment decision and should conduct their own research of the Profiled Companies. The Recipients should not assume that material changes have not occurred since the publication and/or dissemination of in the Information. Each of the Recipients should consult with his or her legal, accounting, tax and financial advisers regarding any investment in the Profiled Companies or the Securities. Use of the Information as well as any investment in micro-cap or penny stock securities are subject to risks and EMC's operational realities, as follows: EMC is not a registered investment advisor or registered securities broker dealer and no information contained within the Information should be construed as investment advice or as a solicitation to offer, purchase or sell the Securities; therefore, you should never use the Information as the only basis upon which you make an investment decision and understand that the use of our Information does not provide you with the possible benefits of receiving advice from a registered investment adviser or registered representative or a broker or dealer. EMC does not provide stock recommendations; as such, none of the Information should be construed directly or indirectly or explicitly or impliedly, as stock recommendations and you should rely upon your professional adviser regarding such matters, including your registered broker, investment adviser or other qualified financial adviser. EMC does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information and conducts no due diligence of the Profiled Companies; Penny stocks are subject to the SEC's penny stock rules, which may cause difficulties in liquidating micro-cap securities; Penny stocks by their very nature involve a high degree of risk and may involve the loss of one's entire investment. Energy, biotech, and other companies are subject to increased regulations, which subject them to material costs and possible fines and liabilities. Because we will sell material amounts of the Securities during the dissemination of the Information, shortly thereafter, or at anytime, our selling activities may negatively cause price volatility, stock price declines and/or increased/decreased selling volume. Because we will buy material amounts of the Securities in the open market before, during or after the dissemination of the Information, these activities may cause price volatility, stock price increases or declines or increased/decreased volume. Because we only present positive or neutral information regarding the Profiled Companies and do not provide negative information in our Profiles, it is all the more important for you to conduct further investigation, consult with outside sources, and consult with your professional adviser. Because we only present selected positive or neutral information, you should consult other recommended sources as we have referred to above, to determine what information is material or immaterial; Because EMC is a Shareholder of the Profiled Companies, it has an inherent conflict of interest with the Recipients, in which EMC may favor their own interests over that of the Recipients, by selling its compensation during the publication of the Information or at anytime. The buying and selling of the Securities by EMC and/or its principals, affiliates and representatives may negatively affect the volume or price of the Securities, including price declines or the common shares becoming unstable. Penny stock securities are often thinly traded, in which case you may have difficulties in liquidating your securities. Penny stock securities involve an extremely high degree of risk. Because the Securities are penny stocks, they are subject to the Securities and Exchange Commission&rsquos penny stock rules, and as such, any investment in the Securities involves a high degree of risk and it may be difficult for any investor or Shareholder to resell the Securities; an investment in the Securities could result in the loss of some or all of an investment. The issuance of the Securities to EMC may cause shareholders and/or investors of the Profiled Companies to experience immediate and substantial dilution of their holdings and/or investments in the Profiled Companies Future securities issuances to EMC for services may also result in a reduction of (i) the book value or market price of the Profiled Companies' securities, (ii) shareholder voting power; and (iii) each shareholder's proportionate ownership of any Profiled Company. You should consider whether the Profiled Company is a development stage company or has little or no operations or no revenues or assets, any such conditions of which increase the risk investment level of investing in such companies. You should consider the financial condition of the Profiled Company in your analysis. Many of the companies are subject to numerous risks particular to the industry that they engage in, which may be disclosed in SEC and/or Pink Sheets reports and we urge you to review. tion 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below: EMC has been paid 350,000 restricted shares from Eagle Ford Oil & Gas Corp.

Results of NurOwn(TM) Clinical Trial Suggest Efficacy in ALS Patients Data Indicate Initial Clinical Benefit in Overall Clinical and Respiratory Function BrainStorm Cell Therapeutics ( OTCQB : BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, today reported some of the final results from a clinical study evaluating the company's NurOwn™ technology in 12 ALS patients. NurOwn is a proprietary, first-of-its-kind technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells. The data were presented yesterday, Wednesday, March 20, 2013 during the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, California. An oral and poster presentation were made in the Emerging Science Session by Principal Investigator Dimitrios Karussis, M.D., Ph.D., entitled, "Analysis of 12 Patients with Amyotrophic Lateral Sclerosis (ALS) Treated with Autologous Differentiated Mesenchymal Stem Cells: a Phase I/II Clinical Trial." Karussis reported a significantly slower decline in overall clinical and respiratory function, as measured by the ALS Functional Rating Score (ALSFRS-R) and Forced Vital Capacity (FVC) score respectively, in the six patients that received an intrathecal (IT) injection of the cells in the six months following treatment, as compared to the three months preceding treatment. The study concluded that in addition to establishing the safety of the treatment protocol, initial indications of clinical benefit were observed, which require further confirmation in additional trials. The company is currently conducting a Phase IIa dose-escalating trial pursuant to recent acceleration by the Israeli Ministry of Health. "These encouraging results confirm the importance and therapeutic potential of NurOwn as a breakthrough treatment for patients with ALS," said Prof. Karussis, Head of the Neuroimmunology Laboratory, Department of Neurology, Hadassah Medical Center, Jerusalem. "Additionally, beyond its benefit in treating patients with ALS, NurOwn may have utility in the treatment of other severe neurodegenerative and neuroimmunological conditions including multiple sclerosis and Parkinson's disease." "We are excited by these data and the potential of NurOwn to positively impact the lives of patients with ALS," said Alon Natanson, Chief Executive Officer of BrainStorm. "We look forward to continuing to advance this potentially important therapy. To that end, we have begun a Phase IIa dose-escalating trial at Hadassah and plan to launch a multi-center Phase II trial in the USA later this year in order to further validate the results that were presented today." About NurOwn™NurOwn is an autologous, adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells (MSC) into specialized, neuron-supporting cells. These neuron-supporting cells (known as "MSC-NTF" cells) secrete neurotrophic, or nerve-growth, factors for PROTECTION of existing motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT of nerve-muscle interaction. The ability to differentiate mesenchymal stem cells into MSC-NTF cells, and confirmation of their activity and potency before transplantation, makes NurOwn a first-of-its-kind approach for treating neurodegenerative diseases. More information about NurOwn™ can be found at http://brainstorm-cell.com/index.php/science-a-technology/-nurown. About ALSOne of the most common neuromuscular diseases worldwide, Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig's disease, is a rapidly progressive, invariably fatal neurological disease that attacks the nerve cells responsible for controlling voluntary muscles. As many as 30,000 people in the United States have ALS and an estimated 5,000 Americans are newly diagnosed each year. The disease belongs to a group of disorders known as motor neuron diseases, which are characterized by the gradual degeneration and death of motor neurons. There is currently no cure available for ALS. About BrainStorm Cell Therapeutics, Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com. Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Contact: CONTACTSBrainStorm Cell Therapeutics Inc. Mr. Alon Natanson CEO Phone: +972-3-9236384 info@brainstorm-cell.com www.brainstorm-cell.com LifeSci Advisors, LLC Michael Rice, Founding Partner 646-597-6979 mrice@lifesciadvisors.com www.LifeSciAdvisors.com _______________________________________ Introduction Investor Presentation – March 2013 BrainStorm Cell Therapeutics (OTC.QB: BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD). NurOwn™, our proprietary, first-of-its-kind technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells and their transplantation at or near the site of damage, offers the hope of conquering neurodegenerative diseases. We are currently conducting a Phase IIa ALS clinical trial with NurOwn at the Hadassah University Medical Center in Jerusalem.  In this safety and preliminary efficacy trial, 12 patients will receive combined intramuscular and intrathecal administration of NurOwn cells in three cohorts with increasing doses. The study participants will be followed for three to six months after transplantation. The company also plans to begin a Phase II clinical trial in the USA in 2013, pending FDA approval. In February 2011, NurOwn was granted Orphan Drug designation by the FDA.   Over 20 publications in leading scientific journals demonstrating NurOwn's mechanism of action, pharmacology and in vivo efficacy have been published by the scientific team. Mission BrainStorm is developing autologous, adult stem cell therapies to treat a variety of debilitating neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's Disease), Parkinson's Disease (PD), and Multiple Sclerosis (MS). Our approach uses the patient's own bone marrow to generate specialized NeuroTrophic Factor (NTF)-secreting cells, which are then transplanted into the spine or muscles, to protect existing motor neurons, promote new motor neuron growth, and re-establish nerve-muscle interaction. We are committed to developing an effective treatment that will overcome the devastating effects of neurodegenerative disease. Stem Cell Therapy Stem Cell therapies are one of the most promising areas of medicine today. The aim of cell therapy is to support and repair damaged tissues and organs by providing healthy stem cell transplants. Bone marrow stem cell transplants for replacement and restoration of the haemopoietic system (blood and lymph) of cancer patients have been successfully used for the past 20 years. Stem cells are generally described as cells that are capable of both self-renewal and differentiation. Stem cells have the ability to undergo asymmetric division such that one of the two daughter cells retains the properties of the stem cell, while the other begins to differentiate into a more specialized cell type. Stem cells are therefore central to normal human growth and development and a potential source of new cells for the regeneration of diseased and damaged tissue. BrainStorm is developing cellular therapeutics based on stem cell technologies. The medical benefits afforded by stem cell therapies offer hope to millions of patients suffering from many types of neuro-degenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, often referred to as Lou Gehrig's Disease), Parkinson’s disease (PD), and Multiple Sclerosis (MS). Management Team Chaim Lebovits President Alon Natanson, MBA CEO Adrian Harel, Ph.D. Director of R&D Liat Sossover, CPA, MBA CFO Prof. Eldad Melamed, M.D. Chief Medical Advisor Prof. Daniel Offen, Ph.D. Chief Scientific Advisor Our Partners Our Partners At BrainStorm we’re interested in exploring strategic partnerships that will further our clinical and technological goals. These academic and clinical collaborations with leading scientific and medical investigators, as well as technological alliances with biotechnology and pharmaceutical companies. We're proud to be partnering today with a leading university medical center and an innovative technology company in the areas of clinical and technology development:    Hadassah Medical Center, JerusalemSince June 2011, BrainStorm has been conducting a Phase I/II clinical trial in patients with ALS at Hadassah Medical Center in Jerusalem. The trial, headed by Prof. Dimitrios Karussis of the Department of Neurology, is designed to evaluate the safety and tolerability of NurOwn™.   Octane Biotech, Kingston, OntarioBrainStorm is collaborating with Octane Biotech to develop a proprietary bioreactor that will optimize the scale-up of the NurOwn production process.  Using Octane’s Automated Cell & Tissue Engineering System (ACTES) technology, we are working on a customized bioreactor that will increase our NurOwn production capabilities and reduce both costs and time.   Headlines Filter Headlines BrainStorm Cell Therapeutics Presents at the 11th International Conference on Alzheimer's and Parkinson's DiseaseMarketwire(Fri, Mar 8) ALS Crisis Of Conscience At FDA Spells Opportunity For Neuralstem, Brainstormat Seeking Alpha(Thu, Mar 7) Rasheda Ali on National and Local News: BrainStorm’s ALS Clinical Trial Results Exceeded ExpectationsBusiness Wire(Wed, Feb 27) BrainStorm to Present at the 8th Annual New York Stem Cell SummitBusiness Wire(Wed, Feb 13) BrainStorm Announces Private Equity Financing of $250,000 with Individual Private InvestorBusiness Wire(Mon, Feb 11) BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online(Fri, Feb 8) First Patient Begins Treatment in BrainStorm’s Phase IIa Trial for ALSBusiness Wire(Mon, Feb 4) BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial StatementsEDGAR Online(Mon, Jan 28) BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive OfficerBusiness Wire(Mon, Jan 28) BrainStorm’s CEO Issues Annual Letter to ShareholdersBusiness Wire(Wed, Jan 23) BrainStorm Establishes Safety of Repeat Doses of NurOwn in Mice; Pre-clinical Study Conducted at GLP-compliant Harlan LaboratoriesBusiness Wire(Thu, Jan 10) BrainStorm Achieves Important New Development for Commercialization of NurOwnBusiness Wire(Wed, Jan 9) BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Jan 8) BrainStorm's Clinical Trial is Fast-Tracked to Phase IIa, Representing a Major Milestone for the CompanyBusiness Wire(Mon, Jan 7) BrainStorm Announces New Shareholders Conference Call Date to Discuss Upcoming Positive DevelopmentsBusiness Wire(Thu, Jan 3) Company Address Brainstorm Cell Therapeutics Inc. 605 Third Avenue 34th Floor New York, NY 10158 United States - Map Phone: 646-666-3188 Website: http://www.brainstorm-cell.com

Share Structure Market Cap 35.27M Avg Volume (3 M) 188,193 52 Week High $0.17 52 Week Low $0.38

Contact James S. Painter III  Emerging Markets Consulting LLC  10724 High Crest Court Howey In The Hills Florida 34737 Office 321-206-6682  Fax 352-429-0691 www.emergingmarketsllc.com  www.themicrocapreport.com Emerging Markets Consulting, LLC ("EMC"), its principals, affiliates, representatives, subcontractors or agents (hereafter referred to as "EMC") prepare and/or assist others in preparing and publishing oral and written information on selected companies (the "Profiled Companies") and/or their securities (the "Securities") in various contexts, including but not limited to corporate and business profiles, summaries, stock alerts, reports, and press releases (hereafter referred to as the "Information") through various methods including but not limited to: (a) facsimile; (b) double opt-in spam compliant emails; (c) mail and courier; and (d) the world wide web, including but not limited to EMC's website at www.emergingmarketsllc.com. Many of the stocks of the Profiled Companies qualify as "penny stocks" under the Securities and Exchange Commission's ("SEC") rules and regulations because, among other things, they have a price of less than $5.00 per share. Penny stocks are subject to important risks that you should be acutely aware of, as detailed in the bullet point presentation below. The Information is disseminated to broker-dealers, members of the general public, readers of our website, and the financial community (collectively the "Recipients") at the direction of the Profiled Companies or third party shareholders of the Profiled Companies and should be used by the Recipients for informational purposes only and even then the Information should only be used as a beginning point for further investigation. This is because EMC: (a) only presents neutral or positive information regarding the Profiled Companies and its business prospects; and (b) does not present the risks or negative aspects associated with the Profiled Company or its securities. Therefore, the Information is in of itself wholly inadequate to formulate any investment decision and we strongly advise against making any investment decisions solely based on the Information. It is imperative that you consult with your professional advisor, including your financial adviser, financial planner or attorney regarding the advisability of investing in any securities, especially with regard to penny stocks. In addition, you should consult with online services that are available free of charge at www.sec.gov, www.pinksheets.com, www.finra.org, Google, or other websites that offer investment guides, valuable information pertaining to penny stocks and penny stock frauds and the risks of investing in penny stocks. Additionally, you should review the quarterly and annual financial and disclosure reports at www.sec.gov, www.otcbb.com and www.pinksheets.com. Statements contained in the Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified by the use of terminology such as "believes", "expects", "may", "will", or "should", or "anticipates". Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Information. The actual results of a Profiled Company's operations, financial condition or other aspects of its business could differ materially from those discussed in the Corporate Information. You should carefully review the bolded disclosure appearing immediately below: EMC always receives compensation from the Profiled Companies or third party shareholders in cash and/or compensation in the Securities in connection with preparation and dissemination of the Information, most frequently in the form of Securities in the name of a Profiled Company. EMC regularly and routinely sells its securities compensation before, during and after its dissemination of the Information regarding the Profiled Companies, most frequently during the dissemination of the Information. You should be acutely aware that EMC repeatedly sells its stock compensation while it is engaged in the dissemination of the Information, as well as before and after such dissemination. Many such securities sales occur during the dissemination of the Information and often occur within minutes, hours or days after EMC first disseminates the Information to the Recipients. EMC's dissemination of the Information has resulted in the past and will in the future result in increases in the Profiled Company's securities trading volume, enabling EMC to sell those Securities at a profit. Additionally, EMC's sale of the Profiled Company's securities concurrently with the dissemination of the Information, including the Profiled Company's profile, may enable EMC to sell at a higher price for such shares, and may result in a diminished value to those buying the Profiled Company's securities.  Emerging Markets Consulting, LLC ("EMC"), its principals, affiliates, representatives, subcontractors or agents (hereafter referred to as "EMC" or “we” or “us”) prepare and/or assist others in preparing and publishing oral and written information on selected companies (the “Profiled Company” ) and their securities (the "Securities") in various contexts, including but not limited to corporate and business profiles, alerts, summaries,  reports, and press releases (hereafter referred to as the "Information") through various methods, including but not limited to: (a)  double opt-in spam compliant emails; (c) mail and courier; (d) EMC’s website’s at profiling the Profiled Company and otherwise through the worldwide web.  In certain cases, we are merely a distributor of such publications, i.e. a Profiled Company’s press release, in which case, as in all other situations, EMC conducts no review of said publications received from any party such as an investor relations firm that directly contracts with a Profiled Company or a third party shareholder.  We do not conduct any due diligence whatsoever for any of our publications, whether we act only as a distributor pursuant to an agreement with another publisher or investor relations firm or directly contract with the Profiled Company or third party shareholder; rather, we rely upon the information of the Profiled Company we receive from the Profiled Company or other investor relations firm or third party shareholder, which similarly may not conduct any due diligence upon the Information. Many of the stocks of the Profiled Company qualify as "penny stocks" under the Securities and Exchange Commission's ("SEC") penny stock rules and regulations because, among other things, they have a price of less than $5.00 per share. Penny stocks are subject to material risks that you should be acutely aware of, as detailed in the bulleted risk factor section  presented below. We are paid to publish the Information about companies that are quoted on the OTCBB, OTC Markets or Pink Sheets or the American Stock Exchange or NASDAQ Small Cap and/or NASDAQ National Market.  We are paid for our services in either money or securities or a combination of cash and securities compensation. The publicly traded companies or third party shareholders or other publishers or investor relations firms that subcontract with us for the services that they have directly contracted for with a publicly traded company or a third party shareholder pay us for our advertisements. We are not independent and the Information published by us is and should be construed as a paid advertisement. We do not conduct research or evaluate if the Information is true, accurate or complete. We are not qualified to give you investment advice. The Information should not be construed as a recommendation to purchase the securities of the Profiled Company or as providing any information that may be construed as investment advice. We are not: (a) an investment advisor; (b) a stock picker; (c) a securities trading expert; (d) a securities analyst; (e) a financial analyst; (f) one that provides stock recommendations, price targets, buy recommendations, stock recommendations for assembling a portfolio of stocks, represents that stocks are undervalued or providing advice about buy and/or sell or hold recommendations as to specific securities; as such, any interpretation of the Information that we furnish should not be construed in any of the foregoing manners. Our advertisements involve an actual conflict of interest, since we receive compensation in the very securities we are promoting and then sell the securities during our  advertorial activities or thereafter. The Profiled Company or investor relations firm or third party shareholder from whom we receive compensation also has an actual conflict of interest since it or he or she pays us securities compensation for advertising services and then may sell their own shares of the Profiled Company while we are publishing the Information about  the Profiled Company or its securities.   A Profiled  Company or third party shareholder or another advertising or investor relations firm that pays us for our advertising services also has a conflict of interest since they are paying us compensation to advertise on their behalf for their own benefit. The Information is disseminated to broker-dealers, members of the general public, readers of our website, and the financial community (collectively the "Recipients") at the direction of the Profiled Company or other investor relations firms or third party shareholders of the Profiled Company or firm hired by the Profiled Company for which we provide subcontracting services or through social media, including Facebook, Twitter, LinkedIn and blog spots.   The Information  should only be used by as a beginning point for further investigation into the Profiled Company and its securities because EMC: (a) only presents neutral or positive information regarding the Profiled Company and its business; (b) does not present the risks or negative aspects associated with the Profiled Company or its securities; and (c) the Information is wholly inadequate to formulate any investment decision; as such we strongly advise against making any investment decisions solely based on the Information. It is imperative that you consult with your professional advisor,  financial adviser, financial planner, registered broker or attorney regarding the advisability of investing in any securities, especially  penny stocks. In addition, you should consult with government or other  websites that are available free of charge at www.sec.gov, www.otcmarkets.com, Google, or other sources that offer specific business and financial information about the Profiled Company, investment guides, valuable information pertaining to penny stocks,  penny stock frauds and penny stock investment risks. Where applicable,  you should review the quarterly (Form 10-Q) and annual (Form 10-K) financial and disclosure reports available at www.sec.gov by visiting said website and inserting the name of the company you wish to inquire about under “Company Search”.  For those companies that are not SEC reporting companies, you should review the quarterly and annual reports available for your review at www.otcmarkets.com Statements contained in the Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified by the use of terminology such as "believes", "expects", "may", "will", or "should", or "anticipates". Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Information. The actual results of a Profiled Company's operations, financial condition or other aspects of its business could differ materially from those discussed in the Information. We do not make any implied or express warranties regarding the Information  -- you should not solely rely upon the Information; rather, again you should use the Information and/or its securities as an initial introduction to the Profiled Company to initiate an investigation into a Profiled Company through, among other sources, information and reports available at the above-listed websites. EMC always receives compensation from the Profiled Company or third party shareholders of the Profiled Company or third-party providers (i.e. another investor relations firm) in cash and/or compensation in the Securities in connection with preparation and dissemination of the Information, most frequently in the form of Securities in the name of a Profiled Company. EMC regularly and routinely sells its securities compensation before, during and after its dissemination of the Information regarding the Profiled Company, most frequently during the dissemination of the Information. You should be acutely aware that EMC repeatedly sells its stock compensation while it is engaged in the dissemination of the Information, as well as before and after such dissemination. Many such securities sales occur during the dissemination of the Information and often occur within minutes, hours or days after EMC first disseminates the Information to the Recipients. EMC's dissemination of the Information has resulted in the past and may in the future result in increases in the Profiled Company's securities trading volume, enabling EMC to sell those Securities at a profit. Additionally, EMC's sale of the Profiled Company's securities concurrently with the dissemination of the Information, including the Profiled Company's profile, may enable EMC to sell at a higher price for such shares, and may result in a diminished value to those buying the Profiled Company's securities. The Securities and Exchange Commission’s regulations provide that “stock scalping”, the illegal practice of recommending that others purchase a security, while secretly selling the same security, contrary to the purchase recommendations is in violation of the anti-fraud provisions of the federal securities laws.  We do not recommend that you purchase the securities of the Profiled Company –  we only introduce a company to the readers of our publications as a starting point for investigating the securities and the Profiled Company through publicly available sources.  We do not conduct any independent analysis regarding a Profiled Company’s Information.  We always disclose the compensation we receive in connection with our publications of the Profiled Company. We do not provide price targets for the companies that we profile.  We do not act in the capacity of an investment advisor.  We do not have control or access over any securities brokerage accounts other than in our own name.  We  do not verbally or in writing recommend that the readers of our publication open brokerage accounts to purchase the securities of a Profiled Company or otherwise recommend that they purchase the Profiled Company’s securities.  Nonetheless, you should be acutely aware that: Pursuant to an agreement between EMC and a Profiled Company, EMC always receives compensation from the Profiled Company or third party shareholder or other investor relations firm in cash and/or securities compensation of the Profiled Company for the services that EMC performs in connection with preparation and/or  dissemination of the Information.  EMC regularly and routinely sells the Profiled Company’s  securities before, during and after its dissemination of the Information regarding the Profiled Company (most frequently during the dissemination of the Information), which may result in substantial profits to EMC; EMC may purchase shares of the Profiled Company before, during and after dissemination of the Information  disseminated by EMC, which may result in substantial profits to EMC;  EMC's dissemination of the Information may result  in increases in the Profiled Company's securities total trading volume or in the purchase volume of the Profiled Company’s securities, enabling EMC to sell its Securities at a profit from the securities compensation it receives for providing services involving publications of the Profiled Company. EMC's sale of the Profiled Company's securities concurrently with the dissemination of the Information, including the Profiled Company's profile, may enable EMC to sell at a higher price for such shares, and may result in a diminished value to those buying the Profiled Company's securities as a result of EMC’s selling activities.   EMC does not express any opinions, recommendations or viewpoints regarding the Profiled Company or the Securities, and has not conducted and due diligence of any data or information contained in the Information. The Information is based solely upon data and information provided by the Profiled Company or third party providers hired by a Profiled Company, a primary distributor of the Information or in connection with subcontracting services that we perform for other investor relations firms.     EMC does not endorse, independently verify, or assert the truthfulness, completeness, accuracy or reliability of the Information;  as such, the Information is presented in an “as is” format and the Recipients should not rely on the data or information contained in the Information in making an investment decision and should conduct their own research of the Profiled Company The Recipients should be especially cautious about any revenue predictions, projected revenues, revenue expectations or any revenue estimates whatsoever (the “Revenue Projections” because: (a) we conduct no due diligence whatsoever on whether the Revenue Projections have a foundational basis and such information should be accepted by us on an “as is” basis; (b) the Revenue Projections may not be in accordance with US Generally Accepted Accounting Principals or SEC guidelines for projections; (c) the Revenue Projections may not contain required assumptions upon which they are based or the assumptions lack a foundational basis for making such Revenue Projections, i.e. based upon a projected agreement with a third party or an actual agreement with a third party, which in of itself may lack or have any foundational basis; (d) we caution you to never use  Revenue Projections as a basis for considering an investment in the subject securities and to proceed with extreme caution regarding the Revenue Projections; instead, only use all of the Information as a starting point for a thorough investigation of the Profiled Company from publicly available sources and determine whether the Revenue Projections have any foundational basis whatsoever; (e)  beware and use extreme caution for any Revenue Projections that fail to include the assumptions upon which they are based; (f) beware and use extreme caution of Revenue Projections that fail to include an evaluation of the support for such assumptions underlying the projections; (g) the Revenue Projections may be inherently unreliable because they are subject to future events wherein a Profiled Company does not update the Financial Projections due to events and circumstances that occur after said projections are released, which may materially and negatively impact upon the Financial Projections; (h) if the Profiled Company is an SEC reporting company the Financial Projections should be in accordance with standards released by the Public Company Accounting Board, the SEC or standards established by the American Institute of Certified Public Accountants, which often a Profiled Company fails to do;  (I) beware of any Financial Projections that fail to include disclosure of the basis of accounting used in preparing the Financial Projections; (j) beware of any Financial Projections that are not prepared or do not indicate whether they are prepared by an independent third party, rather than simply the Profiled Company itself;  (k) consult with your registered investment advisor, registered broker, attorney, or financial advisor regarding  any such Revenue Projections. The Recipients should not assume that material changes have not occurred since the publication and/or dissemination of in the Information. Again, each of the Recipients should consult with his or her legal, accounting, tax and financial advisers regarding any investment in the Profiled Company or its Securities and not rely solely upon the Information, Use of the Information as well as any investment in micro-cap or penny stock securities is subject to  the following risks: EMC is not a registered investment advisor or registered securities broker dealer and no information contained within the Information should be construed as investment advice or as a solicitation to offer, purchase or sell the Securities; therefore, you should never use the Information as the only basis upon which you make an investment decision and understand that the use of our Information does not provide you with the  benefits of receiving advice from a registered investment adviser or registered representative or a broker or dealer and/or conducting an in-depth investigation of  a Profiled Company. EMC does not provide stock recommendations; as such, none of the Information should be construed directly or indirectly or explicitly or impliedly, as stock recommendations and you should rely upon your professional adviser regarding such matters, including your registered broker, investment adviser or other qualified financial adviser. EMC does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information and conducts no due diligence whatsoever of the Profiled Company. Penny stocks are subject to the SEC's penny stock rules, which may cause difficulties in liquidating micro-cap securities; Penny stocks by their very nature involve a high degree of risk and may involve the loss of one's entire investment. Energy, biotech, and other companies are subject to increased regulations, which subject them to material costs and possible fines and liabilities. Because we may sell material amounts of the Securities during the dissemination of the Information, shortly thereafter, or at anytime, our selling activities may negatively cause price volatility, stock price declines and/or increased/decreased selling volume. Because we may purchase  material amounts of the Securities in the open market before, during or after the dissemination of the Information, such activities may cause price volatility, stock price increases or declines or increased/decreased volume. Because we only present positive or neutral information regarding the Profiled Company and do not provide negative information in our Profiles, it is all the more important that  you conduct further investigation of the Profiled Company, consult with outside sources (i.e. www.sec.gov) and consult with your professional adviser.  Additionally, because we only present selected positive or neutral information, when conducting your investigation into the Profiled Company and its securities you should  determine what information is material or immaterial. Because EMC is a Shareholder of the Profiled Company, it has an inherent conflict of interest with the Recipients, wherein EMC may favor their own interests over that of the Recipients in light of the fact that EMC may be selling its own securities of the Profiled Company during its  publication and/or distribution of the Information or at anytime. The buying and selling of the Securities by EMC may negatively affect the volume or price of the Securities, including price declines or price and volume volatility. Penny stock securities are often thinly traded, in which case you may have difficulties in liquidating your securities. Penny stock securities by their very nature involve an extremely high degree of risk. Because the Securities are penny stocks they are subject to the Securities and Exchange Commission's penny stock rules; as such, any investment in the Securities involves a high degree of risk and it may be difficult for any investor or Shareholder to resell the Securities.  An investment in the Profiled Company’s Securities could result in the loss of some or all of an investment in the Profiled Company’s Securities. The issuance of the Securities to EMC may cause shareholders and/or investors of the Profiled Company to experience immediate and substantial dilution of their holdings and/or investments in the Profiled Company Future securities issuances to EMC for services may also result in a reduction of (i) the book value or market price of the Profiled Company’s securities, (ii) shareholder voting power; and (iii) each shareholder's proportionate ownership of any Profiled Company. You should consider whether the Profiled Company is a development stage company or has little or no operations or no revenues or assets, the conditions of which may increase the risk investment level of investing in the Profiled Company.  You should consider the financial condition of the Profiled Company in your analysis by accessing such information from www.sec.gov or www.otcmarkets.com; if such financial information is unavailable from either one of these sites, the risk investment level of investing in any such Profiled Company will be increased. Many of the companies are subject to numerous risks particular to the industry that they engage in. We conduct no due diligence whatsoever regarding: (a) the Issuer; (b) the third party shareholder; and (c) the relationship, if any, between the third party shareholder and the Issuer;  Our trading activities described above may cause: (a) significant volatility in the Issuer's; (b) price declines from our selling activities; (c) an unrealistic report of trading volume, without denoting publicly that we are the primary seller; (d) permit us to make substantial profits while we are disseminating profiles or information about the issuer, yet may result in a diminished value of the Profiled Company’s Securities.   We conduct no due diligence on the press releases or profiles we receive from OTC Markets News Service or other publicly available source, nor do we conduct due diligence on any other information we disseminate to the public.  Penny stocks are subject to the SEC's penny stock rules and subject broker-dealers to customer suitability rules and other requirements, which may lead to low volume in the securities and/or difficulties in selling the shares. We do not assume any responsibility for forward-looking statements nor do we assume any responsibility for updating forward-looking statements. Use of this information is at your own risk and is presented only on an “as is” basis – in other words, you must conduct your own analysis of the risks associated with use of the Information, including its accuracy or reliability. Many penny stocks are thinly traded, which may lead to difficulties in selling your securities and extreme price volatility. Penny stock companies are often subject to extreme regulatory oversight in the industry that they participate in. Penny stock companies are often subject to extreme competition and most frequently have less brand name recognition, operational and personnel resources, technical resources, capital resources, or financing sources.  There is no “right time “to purchase or sell penny stocks or set of factors making it advisable to purchase a Profiled Company’s securities “now”, since at any time such stocks may be subject to price volatility, stock manipulation forces and other negative market forces. A Profiled Company may have negative signs on the otcmarkets.com website that indicate various risks of investing in that individual issuer, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “Pink Sheets – No Information”, which indicates companies that are unable or unwilling to provide disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor”, signifying “Buyer Beware” that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.  The Issuer may be delinquent in its filings with the Securities and Exchange Commission or at otcmarkets.com, which you will be able to determine by accessing the websites at  sec.gov or otcmarkets.com. The stock price and trading volume of any Issuer that we advertise may increase significantly as a result of our dissemination of the Information and then significantly decrease as a result of our or others selling significant or massive quantities of an Issuer;  Many penny stock companies are subject to risks pertaining to the  development stage nature of their business, including that they have failed to provide a proof of concept to their technology or business or their business plan has little if any merit whatsoever.  Many penny stock companies are in need of financing, which they may be unable to obtain on favorable terms or at all. Our advertising activities may cause trading volume of a Profiled Company’s securities to temporarily increase by hundreds or thousands of percent, yet such trading volume may cease at any one time;  Our advertising activities may cause trading volume in Issuers to materially increase, yet such trading volume may cease at any one time, especially if we cease disseminating Information about the Issuers, which will cause difficulties in selling your securities or may be an unrealistic indicator of interest in the Issuer’s securities.  The Information has no predictive value whatsoever of the future stock price of the Profiled Company’s securities   or its  ability to be successful in its business objectives.  Should the SEC determine that inadequate information or irregularities have occurred with a Penny Stock Issuer, they may issue a trading suspension, which will suspend trading in the Issuer’s securities and may for all intents and purposes permanently cease trading because broker-dealers may not accept trades in that particular Issuer’s securities.  The press releases, issuer profiles and information we provide represent only a small amount of information regarding the Issuer, which is insufficient to formulate an investment decision; as such, that information should only be a starting point from which you conduct an in-depth investigation of the issuer from available public sources, such as www.sec.gov, otcmarkets.com, www.sec.gov, yahoofinance.com,www.google.com and other available public sources; and  You should conduct an in-depth investigation of the Profiled Company and its securities  from the above or any other credible available sources, especially because we only present positive information and limited specific information which is an insufficient basis to invest in any stock, yet alone a penny stock; accordingly, you should proceed with an investigation to determine, among other things, information pertaining to the issuer's financial condition, operations, business model, and risks involved in the issuer's business.  Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below. EMC has been Paid 250,000 restricted shares from Brainstorm Emerging Markets Consulting, LLC – All rights reserved.  Any duplication or copying of the foregoing text (in part or in full) or cutting and pasting the foregoing text that is then distributed to the public or through the facilities of interstate commerce constitutes a violation of the copyright laws, making the user of our information subject to a lawsuit for damages, including but not limited to any money the user makes by using the contents of the foregoing text.